Core Insights - Shanghai Medicilon Biopharma Co., Ltd. reported a revenue of 843 million yuan for the first three quarters of 2025, marking a year-on-year increase of 5.14% [1] - The company achieved a net profit of -29.68 million yuan for the same period, a significant reduction in losses by 76.93% compared to the previous year [1] - Medicilon's cash flow from operating activities turned positive, reaching 42.48 million yuan, reflecting a 161.79% year-on-year increase [1] Financial Performance - Revenue for Q3 2025 was 303 million yuan, showing a year-on-year growth of 7.94% and a quarter-on-quarter increase of 10.70% [1] - The net profit for Q3 was -16.79 million yuan, indicating a 71.28% improvement in loss reduction compared to the same quarter last year [1] Innovation and R&D - Medicilon's innovation platform, which integrates AI-driven services, is crucial for enhancing efficiency and attracting client orders [2] - The AI drug discovery platform has successfully assisted multiple innovative drugs in entering clinical trials [2] - The company holds a total of 47 patents, with 7 new patents granted in the first half of 2025, demonstrating its commitment to high investment and efficient R&D [2] Global Expansion - The proportion of overseas revenue increased to 46.54% in the first three quarters of 2025 [3] - Medicilon's Boston laboratories are fully operational, providing services that meet both Chinese and U.S. regulatory standards [3] - The company has successfully passed inspections from major international regulatory bodies, enhancing its global research capabilities [3] Strategic Collaborations - Medicilon has deepened its collaboration with leading domestic pharmaceutical companies, enhancing its capabilities in cutting-edge technology areas [4] - The company has supported several partners in obtaining regulatory approvals for innovative drugs, showcasing its comprehensive technical service capabilities [5] Industry Outlook - The global CRO market is projected to reach $106.45 billion by 2026 and $147.73 billion by 2030, with a compound annual growth rate of approximately 6.6% [5] - The Chinese government has introduced policies to support the CRO industry, providing long-term growth momentum [5]

Core Viewpoint - Medicilon (688202.SH) reported its Q3 2025 results, highlighting an increase in institutional investor holdings and changes in public fund investments [1] Institutional Holdings - As of October 30, 2025, five institutional investors disclosed holdings in Medicilon A-shares, totaling 6.3442 million shares, which represents 4.72% of the total share capital [1] - The institutional holding percentage increased by 1.14 percentage points compared to the previous quarter [1] Public Fund Investments - One public fund, Wan Jia Guo Zheng 2000 ETF, increased its holdings compared to the previous period, showing a slight rise in holding percentage [1] - A new public fund, Qianhai Kaiyuan China Growth Mixed Fund, was disclosed this quarter, while 84 public funds were not disclosed compared to the previous quarter [1]

Core Viewpoint - Meidi Xi (688202) reported a revenue of 843 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 5.14%, while the net profit attributable to shareholders was a loss of 29.68 million yuan, indicating a reduction in losses compared to the previous year [1] Financial Performance - The company's revenue for the first three quarters reached 843 million yuan, marking a 5.14% increase year-on-year [1] - The net profit attributable to shareholders was a loss of 29.68 million yuan, showing a reduction in losses compared to the same period last year [1] Operational Efficiency - The significant reduction in net losses is attributed to the increase in revenue and the company's ongoing efforts to enhance cost control and efficiency [1] - The decrease in operating costs contributed to an improvement in the overall gross profit margin [1]

证券代码：688202 证券简称：美迪西 公告编号：2025-066 上海美迪西生物医药股份有限公司 关于参加 2025 年上海辖区上市公司三季报集体业绩 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过上海美迪西生物医药股 份有限公司（以下简称"公司"）邮箱 IR@medicilon.com.cn 进行提问。公司将在 说明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 13 日（星期四）15:00-16:30 参加 2025 年上海辖区上市公司三季报 集体业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 ...

Group 1 - The core viewpoint of the article highlights that Meidisi (SH 688202) reported a revenue of approximately 843 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 5.14% [1] - The net profit attributable to shareholders of the listed company showed a loss of approximately 29.68 million yuan, with basic earnings per share reflecting a loss of 0.22 yuan [1] - As of the report date, Meidisi's market capitalization stands at 9.7 billion yuan [2]

Financial Performance - The company's operating revenue for the third quarter was ¥302,557,582.07, representing a year-on-year increase of 7.94% and a quarter-on-quarter increase of 10.70%[3]. - The total profit for the period was -¥21,928,490.29, with a significant reduction in losses compared to the previous year, decreasing by ¥119,411,800[10]. - The net profit attributable to shareholders was -¥16,786,543.31, showing a substantial decrease in losses compared to the same period last year[3]. - Total operating revenue for the first three quarters of 2025 reached CNY 842,964,828.95, an increase from CNY 801,725,512.27 in the same period of 2024, reflecting a growth of approximately 5.5%[21]. - Operating profit for the first three quarters of 2025 was reported at -CNY 41,608,143.01, an improvement compared to -CNY 160,506,352.85 in the previous year[22]. - Net profit for the first three quarters of 2025 was -CNY 29,684,899.52, showing a significant reduction in losses compared to -CNY 128,675,088.23 in the same period of 2024[22]. - The total comprehensive income attributable to the parent company for the current period was CNY -29,952,695.06, compared to CNY -128,833,927.60 in the previous period, indicating a significant reduction in losses[23]. Research and Development - Research and development expenses totaled ¥27,570,703.51, accounting for 9.11% of operating revenue, an increase of 0.69 percentage points year-on-year[4]. - Research and development expenses increased to CNY 76,779,670.64 from CNY 71,732,427.38, indicating a rise of approximately 7.3%[21]. Cash Flow and Assets - The cash flow from operating activities for the year-to-date was ¥42,477,694.82, with a year-on-year increase attributed to improved sales collections[10]. - The net cash flow from operating activities for the first three quarters of 2025 was CNY 42,477,694.82, a significant improvement from a net outflow of CNY 68,749,348.95 in the first three quarters of 2024[26]. - The total cash inflow from operating activities for the first three quarters of 2025 was CNY 903,814,198.29, compared to CNY 790,462,601.03 in the same period of 2024, representing an increase of approximately 14.3%[25][26]. - The total assets at the end of the reporting period were ¥2,791,974,814.99, a decrease of 1.11% compared to the end of the previous year[4]. - The total assets of the company amounted to CNY 2,791,974,814.99, slightly down from CNY 2,823,259,680.59 in the previous year[20]. - The company's cash and cash equivalents amounted to approximately ¥383.04 million, an increase from ¥260.53 million as of December 31, 2024, reflecting a growth of 47%[17]. - The cash and cash equivalents at the end of the period in 2025 were CNY 356,644,218.80, compared to CNY 361,806,656.92 at the end of 2024, showing a slight decrease of about 1.3%[27]. Shareholder Information - The top shareholder, Chen Jinzhan, holds 16,362,811 shares, accounting for 12.18% of total shares[12]. - The second-largest shareholder, Chen Jianhuang, owns 9,029,586 shares, which is 6.72% of the total[12]. - The company has not reported any changes in the participation of the top 10 shareholders in the securities lending business compared to the previous period[14]. Operational Status and Future Plans - There are no significant reminders for investors regarding the company's operational status during the reporting period[15]. - The company has not disclosed any new product developments or technological advancements in the current reporting period[15]. - The company has not indicated any plans for market expansion or mergers and acquisitions in the near future[15]. - The financial statements for the quarter have not been subject to any audit opinions[15]. Costs and Liabilities - The company reported a decrease in operating costs by 9.68%, contributing to an improvement in gross profit margin[10]. - Total operating costs decreased to CNY 896,782,662.55 from CNY 956,515,797.05, marking a reduction of about 6.3%[21]. - Total liabilities increased to CNY 728,570,137.65 from CNY 683,102,457.55, reflecting a growth of about 6.7%[19]. - The company reported a decrease in short-term borrowings to CNY 215,953,609.08 from CNY 292,237,608.72, a reduction of approximately 26%[19]. - The total equity attributable to shareholders decreased to CNY 2,063,404,677.34 from CNY 2,140,157,223.04, a decline of about 3.6%[20]. Financial Ratios - The weighted average return on net assets was -0.81%, an increase of 1.64 percentage points compared to the previous year[4]. - The basic and diluted earnings per share for the current period were both CNY -0.22, an improvement from CNY -0.96 in the previous period[23].

Core Insights - The company reported third-quarter revenue of 303 million yuan, representing a year-on-year increase of 7.94% [1] - The net profit for the third quarter was a loss of 16.7865 million yuan [1] - For the first three quarters, the company achieved a revenue of 843 million yuan, reflecting a year-on-year growth of 5.14% [1] - The net profit for the first three quarters was a loss of 29.6849 million yuan [1]

Core Points - Shanghai Medicilon Inc. (the "Company") announced that shareholder Lin Changqing has released a portion of his pledged shares [2] - Lin Changqing holds a total of 4,113,654 shares, representing 3.06% of the Company's total equity [2] - The release involves 1,050,000 shares, leaving Lin with 2,400,000 pledged shares, which is 58.34% of his total holdings and 1.79% of the Company's total equity [2] Summary of Events - The Company received notification from shareholder Lin Changqing regarding the completion of the share pledge release [2] - The data provided is based on the shareholding as of October 24, 2025 [2] - The Company will fulfill its information disclosure obligations in case of any significant changes regarding the pledge [3]

证券代码：688202 证券简称：美迪西 公告编号：2025-065 上海美迪西生物医药股份有限公司 2025 年员工持股计划完成股票非交易过户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 10 月 27 日，公司收到中国证券登记结算有限责任公司出具的《证 券过户登记确认书》，确认公司回购专用证券账户（证券账户号码：B886178428） 所持有的 1,371,948 股公司股票已于 2025 年 10 月 24 日非交易过户至"上海美迪 西生物医药股份有限公司－2025 年员工持股计划"证券账户（证券账户号码： B887678926），过户价格为 17.45 元/股。截至本公告披露日，本员工持股计划证 券账户持有公司股份数量为 1,371,948 股，占公司当前总股本的比例为 1.02%。 根据《上海美迪西生物医药股份有限公司 2025 年员工持股计划（草案）》 的相关规定，本员工持股计划的存续期不超过 24 个月，所获标的股票的锁定期 为 12 个月，自公司公告最后一笔标的股票过户至本员工持股计 ...

公司于近日接到股东林长青通知，获悉其所持有公司的部分股份办理了解除 质押手续，具体事项如下： | 股东名称 | 林长青 | | --- | --- | | 本次解除质押股份 | 股 1,050,000 | | 占其所持股份比例 | 25.52% | | 占公司总股本比例 | 0.78% | | 解除质押时间 | 年 月 日 2025 10 23 | | 持股数量 | 4,113,654 股 | 一、 本次股份解除质押情况 1 | 持股比例 | 3.06% | | --- | --- | | 剩余被质押股份数量 | 股 2,400,000 | | 剩余被质押股份占其所持股份比例 | 58.34% | | 剩余被质押股份占公司总股本比例 | 1.79% | 证券代码：688202 证券简称：美迪西 公告编号：2025-064 上海美迪西生物医药股份有限公司 关于股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 上海美迪西生物医药股份有限公司（以下简称"公司"）股东林长青持有 公司股份 ...